Search research articles
Contact Us
Filters
Showing results (21-30 of 82) with videos related to
Page
of 9
Sort By:
Haematologica
|
November 24, 2022
<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
Rami Komrokji, Najla Al Ali, Onyee Chan, et al.
Hematology (Amsterdam, Netherlands)
|
May 24, 2021
Impact of obesity on survival of patients with myelodysplastic syndromes
Zaker Schwabkey, Najla Al Ali, David Sallman, et al.
Leukemia Research
|
October 20, 2018
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Kendra Sweet, Lori Hazlehurst, Eva Sahakian, et al.
American Journal of Hematology
|
August 25, 2019
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
American Journal of Hematology
|
November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Blood Cancer Journal
|
November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
Rami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms
Franco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 12, 2020
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis
Franco Castillo-Tokumori, Chetasi Talati, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 15, 2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
Abu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, et al.
American Journal of Hematology
|
December 23, 2016
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience
Patrick T Griffin, Rami S Komrokji, Kendra Sweet, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 82) with videos related to
Sort By:
Page
of 9
Haematologica
|
November 24, 2022
<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
Rami Komrokji, Najla Al Ali, Onyee Chan, et al.
Hematology (Amsterdam, Netherlands)
|
May 24, 2021
Impact of obesity on survival of patients with myelodysplastic syndromes
Zaker Schwabkey, Najla Al Ali, David Sallman, et al.
Leukemia Research
|
October 20, 2018
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Kendra Sweet, Lori Hazlehurst, Eva Sahakian, et al.
American Journal of Hematology
|
August 25, 2019
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
American Journal of Hematology
|
November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Blood Cancer Journal
|
November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
Rami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms
Franco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 12, 2020
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis
Franco Castillo-Tokumori, Chetasi Talati, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 15, 2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
Abu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, et al.
American Journal of Hematology
|
December 23, 2016
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience
Patrick T Griffin, Rami S Komrokji, Kendra Sweet, et al.
Page
of 9